Resmetirom for the treatment of nonalcoholic steatohepatitis: Evaluating the robustness of available evidence

Non-alcoholic steatohepatitis (NASH), recently renamed metabolic dysfunction-associated steatohepatitis (MASH) [1] is still an orphan condition, with no pharmacological therapy yet approved for use in clinical practice. Nonetheless, the clinical trial landscape in the field is rapidly changing with several molecules currently being studied in Phase 3 clinical programs. In particular, thyroid hormone beta receptor (TRB) agonists have received considerable attention as they reduce de novo lipogenesis, promote fatty acid oxidation, modulate mitophagy and mitochondrial biogenesis as well as cholesterol metabolism and potentially exert direct anti-inflammatory and anti-fibrotic effects.
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Correspondence Source Type: research